Table 2.

Frequency (unweighted and weighted), prevalence of lower-body functional limitations (LBFL, 95% confidence interval), and unadjusted prevalence odds ratio (and 95% confidence interval) by type of long-term cancer survivor, 2005-2007.^*

Type of cancer	Unweighted frequency	Weighted frequency	Prevalence of LBFL	95% confidence interval	Odds ratio**	95% confidence interval
Bladder	60	177,280	51.6	36.1 – 66.8	2.94	1.56 – 5.55
Breast	583	1,372,577	60.6	56.1 – 64.9	4.24	3.53 – 5.10
Cervical	299	784,913	47.1	40.5 – 53.8	2.46	1.88 – 3.22
Colorectal	199	469,900	61.8	54.1 – 68.9	4.46	3.25 – 6.13
Lung	53	125,412	88.8	77.1 – 94.9	21.97	9.34 – 51.71
Lymphoma	77	246,780	44.9	32.6 – 57.8	2.25	1.34 – 3.79
Melanoma	197	562,446	46.5	38.3 – 54.9	2.46	1.71 – 3.36
Ovarian	95	207,565	52.8	41.3 – 64.0	3.09	1.95 – 4.92
Prostate	337	904,315	59.3	52.7 – 65.5	4.02	3.08 – 5.25
Thyroid	67	201,500	57.6	42.3 – 71.7	3.76	2.03 – 6.98
Uterus	194	518,419	67.3	58.9 – 74.7	5.68	3.95 – 8.17

^*Types of cancers which had been reported by at least 50 respondents.

^**Versus persons without cancer